How to buy Seres Therapeutics stock

Seres Therapeutics, Inc is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Seres Therapeutics employs 108 staff and has a trailing 12-month revenue of around USD$23.3 million.

How to buy shares in Seres Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Seres Therapeutics. Find the stock by name or ticker symbol: MCRB. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Seres Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Seres Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Seres Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. MCRB shares summary
2. Compare share dealing platforms
3. Is MCRB stock a buy or sell?
4. Stock performance over time
5. Can I short MCRB shares?
6. Seres Therapeutics's financials
7. How volatile are MCRB shares?
8. Does Seres Therapeutics pay a dividend?
9. Other common questions

Seres Therapeutics share price

Use our graph to track the performance of MCRB stocks over time.

Seres Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-03.

52-week range	USD$2.52 - USD$38.5
50-day moving average	USD$24.2682
200-day moving average	USD$27.029
Wall St. target price	USD$37.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.866

Buy Seres Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Seres Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Seres Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Seres Therapeutics shares

There are currently 6.0 million Seres Therapeutics shares held short by investors – that's known as Seres Therapeutics's "short interest". This figure is 14.3% down from 7.0 million last month.

There are a few different ways that this level of interest in shorting Seres Therapeutics shares can be evaluated.

Seres Therapeutics's "short interest ratio" (SIR)

Seres Therapeutics's "short interest ratio" (SIR) is the quantity of Seres Therapeutics shares currently shorted divided by the average quantity of Seres Therapeutics shares traded daily (recently around 932642.56651017). Seres Therapeutics's SIR currently stands at 6.39. In other words for every 100,000 Seres Therapeutics shares traded daily on the market, roughly 6390 shares are currently held short.

However Seres Therapeutics's short interest can also be evaluated against the total number of Seres Therapeutics shares, or, against the total number of tradable Seres Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seres Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Seres Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.1109% of the tradable shares (for every 100,000 tradable Seres Therapeutics shares, roughly 111 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Seres Therapeutics.

Find out more about how you can short Seres Therapeutics stock.

Seres Therapeutics share price volatility

Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $2.52 up to $38.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 3.9989. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Seres Therapeutics overview

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Seres Therapeutics is owned by insiders or institutions?

  Currently 9.261% of Seres Therapeutics shares are held by insiders and 81.196% by institutions.

• How many people work for Seres Therapeutics?

  Latest data suggests 108 work at Seres Therapeutics.

• When does the fiscal year end for Seres Therapeutics?

  Seres Therapeutics's fiscal year ends in December.

• Where is Seres Therapeutics based?

  Seres Therapeutics's address is: 200 Sidney Street, Cambridge, MA, United States, 02139

• What is Seres Therapeutics's ISIN number?

  Seres Therapeutics's international securities identification number is: US81750R1023

• What is Seres Therapeutics's CUSIP number?

  Seres Therapeutics's Committee on Uniform Securities Identification Procedures number is: 81750R102